Clindamycin Phosphate for Glioblastoma (GBM)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Glioblastoma (GBM)+2 MoreClindamycin Phosphate - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects for people being treated with Tumor Treating Fields for malignant glioma.

Eligible Conditions
  • Glioblastoma (GBM)
  • Skin Toxicities
  • Glioblastoma

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: up to 120 days

up to 120 days
Number of patients without grade 2 or higher skin toxicity
skin-related quality of life

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

topical clindamycin and triamcinolone
1 of 1

Experimental Treatment

58 Total Participants · 1 Treatment Group

Primary Treatment: Clindamycin Phosphate · No Placebo Group · Phase 2

topical clindamycin and triamcinoloneExperimental Group · 2 Interventions: Triamcinolone Acetonide, Clindamycin Phosphate · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Triamcinolone
FDA approved
Clindamycin
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 120 days

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,834 Previous Clinical Trials
588,305 Total Patients Enrolled
Mario Lacouture, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
6 Previous Clinical Trials
1,774 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are able to self-administer topical agents or have another person who can apply the topical agents.
Treatment with TTF should be initiated within 7 days of planned initiation on this trial.